参考文献/References:
[1]Siewert JR,Stein HJ.Classification of adenocarcinoma of the oesophagogastric junction[J].Br J Surg,1998,85(11):1457-1459.[2]Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.[3]Al-Batran SE,Homann N,Pauligk C,et al.Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial[J].Lancet,2019,393(10184):1948-1957.[4]Rotte A,Jin JY,Lemaire V.Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy[J].Ann Oncol,2018,29(1):71-83.[5]Bang YJ,Cho JY,Kim YH,et al.Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer[J].Clin Cancer Res,2017,23(19):5671-5678.[6]Janjigian YY,Bendell J,Calvo E,et al.CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer[J].J Clin Oncol,2018,36(28):2836-2844.[7]Tang Q,Chen Y,Li X,et al.The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers[J].Front Immunol,2022,13:964442.[8]Thompson ED,Zahurak M,Murphy A,et al.Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma[J].Gut,2017,66(5):794-801.[9]Shitara K,?魻zgüroglu M,Bang YJ,et al.Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J].Lancet,2018,392(10142):123-133.[10]Fuchs CS,?魻zgüroglu M,Bang YJ,et al.Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial[J].Gastric Cancer,2022,25(1):197-206.[11]Chung HC,Kang YK,Chen Z,et al.Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients[J].Cancer,2022,128(5):995-1003.[12]Shitara K,Van Cutsem E,Bang YJ,et al.Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial[J].JAMA Oncol,2020,6(10):1571-1580.[13]Xu J,Jiang H,Pan Y,et al.Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial[J].JAMA,2023,330(21):2064-2074.[14]Janjigian YY,Shitara K,Moehler M,et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J].Lancet,2021,398(10294):27-40.[15]Kawazoe A,Yamaguchi K,Yasui H,et al.Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study[J].Eur J Cancer,2020,129:97-106.[16]Shah MA,Kennedy EB,Alarcon-Rozas AE,et al.Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline[J].J Clin Oncol,2023,41(7):1470-1491.[17]Grizzi G,Petrelli F,Di Bartolomeo M,et al.Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis[J].Gastric Cancer,2022,25(5):982-987.[18]van Hagen P,Hulshof MC,van Lanschot JJ,et al.Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.[19]Shapiro J,van Lanschot JJB,Hulshof MCCM,et al.Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J].Lancet Oncol,2015,16(9):1090-1098.[20]Weichselbaum RR,Liang H,Deng L,et al.Radiotherapy and immunotherapy: a beneficial liaison?[J].Nat Rev Clin Oncol,2017,14(6):365-379.[21]Tang Z,Wang Y,Liu D,et al.The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction[J].Nat Commun,2022,13(1):6807.[22]Shah MA,Almhanna K,Iqbal S,et al.Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC)[J].J Clin Oncol,2021,39(15_Suppl):4005.[23]Zhu M,Chen C,Foster NR,et al.Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction[J].Clin Cancer Res,2022,28(14):3021-3031.[24]Kim R,An M,Lee H,et al.Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer[J].Cancer Discov,2022,12(4):984-1001.[25]Jiang H,Yu X,Li N,et al.Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study[J].J Immunother Cancer,2022,10(3):e003635.[26]Yin Y,Lin Y,Yang M,et al.Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial[J].Front Oncol,2022,12:959295.[27]Zhou M,Yang W,Xuan Y,et al.A study protocol of a randomized phase Ⅱ trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study[J].BMC Cancer,2022,22(1):710.[28]Klevebro F,Johnsen G,Johnson E,et al.Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation[J].Eur J Surg Oncol,2015,41(7):920-926.[29]Yoshida T,Ogura G,Tanabe M,et al.Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan[J].Cancer Biol Ther,2022,23(1):191-200.[30]Chao J,Fuchs CS,Shitara K,et al.Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials[J].JAMA Oncol,2021,7(6):895-902.[31]André T,Tougeron D,Piessen G,et al.Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study[J].J Clin Oncol,2023,41(2):255-265.[32]Mokdad AA,Yopp AC,Polanco PM,et al.Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis[J].JAMA Oncol,2018,4(1):31-38.[33]Kelly RJ,Ajani JA,Kuzdzal J,et al.Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer[J].N Engl J Med,2021,384(13):1191-1203.[34]Mamdani H,Schneider B,Perkins SM,et al.A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study[J].Front Oncol,2021,11:736620.[35]Bratman SV,Yang SYC,Iafolla MAJ,et al.Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab[J].Nat Cancer,2020,1(9):873-881.[36]Park R,Da Silva LL,Saeed A.Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond[J].Cancers (Basel),2021,13(7):1715.[37]Zhou KI,Peterson B,Serritella A,et al.Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy[J].Clin Cancer Res,2020,26(24):6453-6463.
相似文献/References:
[1]陈 旸,曾 川,张献全.肝细胞肝癌的靶向及免疫治疗研究现状与进展[J].医学信息,2019,32(03):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
CHEN Yang,ZENG Chuan,ZHANG Xian-quan.Current Status and Progress of Research on Hepatocellular Carcinoma Targeting and Immunotherapy[J].Journal of Medical Information,2019,32(20):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
[2]刘 丽,孙立新,赵明珍,等.干扰素-γ对乳腺癌细胞HLA-Ⅰ分子表达的影响[J].医学信息,2019,32(04):88.[doi:10.3969/j.issn.1006-1959.2019.04.029]
LIU Li,SUN Li-xin,ZHAO Ming-zhen,et al.Effect of Interferon-γ on HLA-Ⅰ Expression in Breast Cancer Cells[J].Journal of Medical Information,2019,32(20):88.[doi:10.3969/j.issn.1006-1959.2019.04.029]
[3]李芮蝶,朱雪莉,陈 鑫.三阴乳腺癌分型与临床药物治疗的研究[J].医学信息,2020,33(05):40.[doi:10.3969/j.issn.1006-1959.2020.05.013]
LI Rui-die,ZHU Xue-li,CHEN Xin.Study on the Classification of Triple Negative Breast Cancer and Clinical Drug Therapy[J].Journal of Medical Information,2020,33(20):40.[doi:10.3969/j.issn.1006-1959.2020.05.013]
[4]刘 垚,钱有辉.ctDNA检测及靶向药物在非小细胞肺癌中的应用[J].医学信息,2020,33(11):38.[doi:10.3969/j.issn.1006-1959.2020.11.013]
LIU Yao,QIAN You-hui.Detection of ctDNA and Application of Targeted Drugs in Non-small Cell Lung Cancer[J].Journal of Medical Information,2020,33(20):38.[doi:10.3969/j.issn.1006-1959.2020.11.013]
[5]罗 红,张瑞新,宁方玲.抗肿瘤血管靶向药物的作用及应用研究[J].医学信息,2021,34(06):40.[doi:10.3969/j.issn.1006-1959.2021.06.011]
LUO Hong,ZHANG Rui-xin,NING Fang-ling.Research on the Effect and Application of Anti-tumor Blood Vessel Targeting Drugs[J].Journal of Medical Information,2021,34(20):40.[doi:10.3969/j.issn.1006-1959.2021.06.011]
[6]肖云露,江 涛.侵袭性肺曲霉病的防治[J].医学信息,2021,34(06):43.[doi:10.3969/j.issn.1006-1959.2021.06.012]
XIAO Yun-lu,JIANG Tao.Prevention and Treatment of Invasive Pulmonary Aspergillosis[J].Journal of Medical Information,2021,34(20):43.[doi:10.3969/j.issn.1006-1959.2021.06.012]
[7]王 超.非小细胞肺癌免疫治疗的研究[J].医学信息,2021,34(11):57.[doi:10.3969/j.issn.1006-1959.2021.11.017]
WANG Chao.Research on Immunotherapy of Non-small Cell Lung Cancer[J].Journal of Medical Information,2021,34(20):57.[doi:10.3969/j.issn.1006-1959.2021.11.017]
[8]李一鸣,陈文翔,王 禹,等.肝癌预后模型的构建及其在免疫治疗中的作用研究[J].医学信息,2022,35(04):68.[doi:10.3969/j.issn.1006-1959.2022.04.018]
LI Yi-ming,CHEN Wen-xiang,WANG Yu,et al.The Construction of a Prognostic Model for Hepatocellular Carcinomaand its Role in Immunotherapy[J].Journal of Medical Information,2022,35(20):68.[doi:10.3969/j.issn.1006-1959.2022.04.018]
[9]巴 颖,张核子,余晨笛,等.基于TCGA数据库构建和评估口腔癌的免疫相关预后模型[J].医学信息,2022,35(06):14.[doi:10.3969/j.issn.1006-1959.2022.06.004]
BA Ying,ZHANG He-zi,YU Chen-di,et al.Construction and Evaluation of Immune Related Prognosis Model of Oral Cancer Based on TCGA Database[J].Journal of Medical Information,2022,35(20):14.[doi:10.3969/j.issn.1006-1959.2022.06.004]
[10]李书有.中晚期肝癌的非手术综合治疗[J].医学信息,2022,35(09):73.[doi:10.3969/j.issn.1006-1959.2022.09.018]
LI Shu-you.Non-surgical Comprehensive Treatment for Advanced Liver Cancer[J].Journal of Medical Information,2022,35(20):73.[doi:10.3969/j.issn.1006-1959.2022.09.018]